Thales to Provide Mobile Driver Licenses to State of Florida
13.10.2020 16:00:00 EEST | Business Wire | Press release
The State of Florida will be the first state in the United States to provide mobile Driver Licenses with leading-edge security mechanisms, fully compliant with rigorous national and international standards. Thales will supply the Florida Department of Highway Safety and Motor Vehicles with mobile Driver License verification services, as well as a mobile Driver License solution for residents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005021/en/
(Photo: Business Wire)
In 2021, Florida residents will be able to apply for new mobile Driver Licenses that are easily accessible on a variety of devices, including smartphones and tablets. These mobile Driver Licenses meet the national and international standards from the American Association of Motor Vehicle Administrators and the International Organization for Standardization, meaning they can be used across the United States and internationally.
These new mobile Driver Licenses have the same validity as traditional driver’s licenses to verify identity, including proof of age and driving privileges. It also provides an additional role as a strong authentication tool, enabling Floridians to securely prove who they are online for a variety of services.
Now, to complement the traditional use of driver licenses to prove their identity, Florida residents will be able to simply activate their mobile identification application, select the type of verification needed, and hold up their mobile device. The mobile device never leaves the owners hand, making it a contact-free and convenient way to show ID.
“I’m excited for this innovation project that will make the state of Florida a national leader in offering secure and trusted mobile identification, which is a priority for our Governor, Ron DeSantis,” said Terry L. Rhodes, Executive Director of the Florida Department of Highway Safety and Motor Vehicles. “We have made a sustained commitment to the modernization of nearly every aspect of what our department does and how customers access our services, and Thales will be a great partner as Florida now steps into the future of mobile identification.”
“As ID fraud becomes more frequent and sophisticated, we made it a priority to reinforce ID verification by adding extra software security technologies. In the future, enterprises such as airports, hotels, car rental companies etc, in Florida will be able to rely on Thales to identify customers, while guaranteeing their privacy”, said Tony Lo Brutto, VP NORAM, Identity and Biometric Solutions at Thales.
These mobile Driver Licenses are harder to counterfeit, as they host a secure digitized credential whose authenticity can be checked rather than simply displaying a digital image of a driver license that could be easily manipulated.
For stronger privacy, users of mobile Driver Licenses control what information is displayed from the app depending on the context. For example, to enter a casino it only needs to show that the individual is old enough and the mobile Driver License will just display that information – not the individual’s name, date of birth, or address.
The Florida mobile Driver License program builds on Thales’ strong foundation of supporting state identity programs for 11 other U.S. states and five Canadian provinces.
Note to Editors
Thales, a leader in mobile driver’s license technology, successfully conducted the first U.S. mobile Driver’s License or Digital Driver’s License pilots across multiple states through a partnership and grant awarded in 2016 by the U.S. National Institute of Standards and Technology. Thales has recently been nationally recognized for the Digital ID Wallet, which incorporates the mobile Driver’s License solution, by Frost & Sullivan and ABI Research
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Download HD pictures
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005021/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
Vanessa.viala@thalesgroup.com
Thales, Media Relations
USA
Adam Kostecki
+1 (703) 838-5645
adam.kostecki@us.thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom